Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 30189250)

  • 1. Targeting the paracrine hormone-dependent guanylate cyclase/cGMP/phosphodiesterases signaling pathway for colorectal cancer prevention.
    Yarla NS; Gali H; Pathuri G; Smriti S; Farooqui M; Panneerselvam J; Kumar G; Madka V; Rao CV
    Semin Cancer Biol; 2019 Jun; 56():168-174. PubMed ID: 30189250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention.
    Weinberg DS; Lin JE; Foster NR; Della'Zanna G; Umar A; Seisler D; Kraft WK; Kastenberg DM; Katz LC; Limburg PJ; Waldman SA
    Cancer Prev Res (Phila); 2017 Jun; 10(6):345-354. PubMed ID: 28396341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guanylyl cyclase C signaling axis and colon cancer prevention.
    Pattison AM; Merlino DJ; Blomain ES; Waldman SA
    World J Gastroenterol; 2016 Sep; 22(36):8070-7. PubMed ID: 27688649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guanylyl Cyclase C Hormone Axis at the Intersection of Obesity and Colorectal Cancer.
    Blomain ES; Merlino DJ; Pattison AM; Snook AE; Waldman SA
    Mol Pharmacol; 2016 Sep; 90(3):199-204. PubMed ID: 27251363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling.
    Lin JE; Li P; Snook AE; Schulz S; Dasgupta A; Hyslop TM; Gibbons AV; Marszlowicz G; Pitari GM; Waldman SA
    Gastroenterology; 2010 Jan; 138(1):241-54. PubMed ID: 19737566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity-Induced Colorectal Cancer Is Driven by Caloric Silencing of the Guanylin-GUCY2C Paracrine Signaling Axis.
    Lin JE; Colon-Gonzalez F; Blomain E; Kim GW; Aing A; Stoecker B; Rock J; Snook AE; Zhan T; Hyslop TM; Tomczak M; Blumberg RS; Waldman SA
    Cancer Res; 2016 Jan; 76(2):339-46. PubMed ID: 26773096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer.
    Rappaport JA; Waldman SA
    Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1125-1137. PubMed ID: 32945718
    [No Abstract]   [Full Text] [Related]  

  • 8. The Guanylate Cyclase C-cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia.
    Rappaport JA; Waldman SA
    Front Oncol; 2018; 8():299. PubMed ID: 30131940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. APC-β-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axis.
    Blomain ES; Rappaport JA; Pattison AM; Bashir B; Caparosa E; Stem J; Snook AE; Waldman SA
    Cancer Biol Ther; 2020 May; 21(5):441-451. PubMed ID: 32037952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential.
    Entezari AA; Snook AE; Waldman SA
    Expert Opin Ther Targets; 2021 May; 25(5):335-346. PubMed ID: 34056991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A uroguanylin-GUCY2C endocrine axis regulates feeding in mice.
    Valentino MA; Lin JE; Snook AE; Li P; Kim GW; Marszalowicz G; Magee MS; Hyslop T; Schulz S; Waldman SA
    J Clin Invest; 2011 Sep; 121(9):3578-88. PubMed ID: 21865642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer.
    Wilson C; Lin JE; Li P; Snook AE; Gong J; Sato T; Liu C; Girondo MA; Rui H; Hyslop T; Waldman SA
    Cancer Epidemiol Biomarkers Prev; 2014 Nov; 23(11):2328-37. PubMed ID: 25304930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ST-Producing E. coli Oppose Carcinogen-Induced Colorectal Tumorigenesis in Mice.
    Li P; Lin JE; Snook AE; Waldman SA
    Toxins (Basel); 2017 Sep; 9(9):. PubMed ID: 28895923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal GUCY2C prevents TGF-β secretion coordinating desmoplasia and hyperproliferation in colorectal cancer.
    Gibbons AV; Lin JE; Kim GW; Marszalowicz GP; Li P; Stoecker BA; Blomain ES; Rattan S; Snook AE; Schulz S; Waldman SA
    Cancer Res; 2013 Nov; 73(22):6654-66. PubMed ID: 24085786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer.
    Aka AA; Rappaport JA; Pattison AM; Sato T; Snook AE; Waldman SA
    Expert Rev Clin Pharmacol; 2017 May; 10(5):549-557. PubMed ID: 28162021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GUCY2C ligand replacement to prevent colorectal cancer.
    Blomain ES; Pattison AM; Waldman SA
    Cancer Biol Ther; 2016 Jul; 17(7):713-8. PubMed ID: 27104761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers.
    Weinberg DS; Foster NR; Della'Zanna G; McMurray RP; Kraft WK; Pallotto A; Kastenberg DM; Katz LC; Henry CH; Moleski SM; Limburg PJ; Waldman SA
    Cancer Biol Ther; 2021 Dec; 22(10-12):544-553. PubMed ID: 34632925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intestinal neuropod cell GUCY2C regulates visceral pain.
    Barton JR; Londregan AK; Alexander TD; Entezari AA; Bar-Ad S; Cheng L; Lepore AC; Snook AE; Covarrubias M; Waldman SA
    J Clin Invest; 2023 Feb; 133(4):. PubMed ID: 36548082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guanylin peptides and colorectal cancer (CRC).
    Camici M
    Biomed Pharmacother; 2008 Feb; 62(2):70-6. PubMed ID: 17582727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome.
    Li P; Wuthrick E; Rappaport JA; Kraft C; Lin JE; Marszalowicz G; Snook AE; Zhan T; Hyslop TM; Waldman SA
    Cancer Res; 2017 Sep; 77(18):5095-5106. PubMed ID: 28916678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.